BidaskClub downgraded shares of Illumina (NASDAQ:ILMN) from a buy rating to a hold rating in a research report released on Tuesday, BidAskClub reports.

Other equities analysts also recently issued research reports about the stock. Cowen dropped their price target on shares of Illumina from $380.00 to $320.00 and set an outperform rating for the company in a research note on Friday, July 12th. Deutsche Bank dropped their price target on shares of Illumina from $290.00 to $280.00 and set a hold rating for the company in a research note on Friday, July 12th. Piper Jaffray Companies dropped their price target on shares of Illumina from $382.00 to $348.00 and set an overweight rating for the company in a research note on Tuesday, July 30th. Argus dropped their price target on shares of Illumina to $340.00 and set a buy rating for the company in a research note on Thursday, July 18th. Finally, Wolfe Research assumed coverage on shares of Illumina in a research note on Thursday, May 30th. They set an outperform rating for the company. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and eleven have assigned a buy rating to the stock. The company has an average rating of Buy and a consensus price target of $330.92.

Shares of NASDAQ:ILMN opened at $288.58 on Tuesday. The company has a market cap of $41.84 billion, a price-to-earnings ratio of 50.45, a PEG ratio of 2.65 and a beta of 1.10. The company has a debt-to-equity ratio of 0.42, a current ratio of 6.79 and a quick ratio of 6.10. The firm has a 50 day simple moving average of $308.54 and a 200 day simple moving average of $315.16. Illumina has a one year low of $268.62 and a one year high of $380.76.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Monday, July 29th. The life sciences company reported $1.35 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.32 by $0.03. The business had revenue of $838.00 million during the quarter, compared to the consensus estimate of $835.12 million. Illumina had a net margin of 27.56% and a return on equity of 21.73%. The firm’s revenue was up 1.0% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.43 EPS. As a group, analysts expect that Illumina will post 6.04 EPS for the current year.

In other news, SVP Charles Dadswell sold 1,220 shares of the stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $309.70, for a total transaction of $377,834.00. Following the completion of the sale, the senior vice president now directly owns 8,006 shares in the company, valued at $2,479,458.20. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, SVP Mostafa Ronaghi sold 10,000 shares of the stock in a transaction on Thursday, August 15th. The stock was sold at an average price of $285.52, for a total transaction of $2,855,200.00. Following the sale, the senior vice president now owns 86,585 shares of the company’s stock, valued at $24,721,749.20. The disclosure for this sale can be found here. Insiders have sold 60,458 shares of company stock valued at $19,329,754 in the last ninety days. Insiders own 0.38% of the company’s stock.

Several institutional investors and hedge funds have recently bought and sold shares of ILMN. Next Capital Management LLC acquired a new stake in shares of Illumina during the second quarter worth $25,000. Strategy Asset Managers LLC acquired a new stake in shares of Illumina during the first quarter worth $26,000. C J Advisory Inc acquired a new stake in shares of Illumina during the first quarter worth $29,000. Mizuho Securities Co. Ltd. acquired a new stake in shares of Illumina during the first quarter worth $37,000. Finally, Harel Insurance Investments & Financial Services Ltd. acquired a new stake in shares of Illumina during the second quarter worth $37,000. Institutional investors own 92.09% of the company’s stock.

Illumina Company Profile

Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.

Featured Story: Catch-Up Contributions

Analyst Recommendations for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.